OKYO Pharma CEO reports stock option holdings
OKYO Pharma Ltd filed a Form 3 showing that Chief Executive Officer Robert John Dempsey holds four stock option positions over its common stock.
Rhea-AI Filing Summary
OKYO Pharma Ltd filed a Form 3 showing that Chief Executive Officer Robert John Dempsey holds four stock option positions over its common stock. Each option position relates to 400,000 shares of common stock at an exercise price of $2.2300 per share.
The options have staggered exercise dates on January 2, 2027, January 2, 2028, January 2, 2029, and January 2, 2030, and all are scheduled to expire on January 2, 2036. The filing records these as existing holdings rather than new market transactions.
Positive
- None.
Negative
- None.
Insider Trade Summary
4 transactions reported
Mixed
4 txns
Insider
Dempsey Robert John
Role
CHIEF EXECUTIVE OFFICER
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| holding | Options | -- | -- | -- |
| holding | Options | -- | -- | -- |
| holding | Options | -- | -- | -- |
| holding | Options | -- | -- | -- |
Holdings After Transaction:
Options — 1,600,000 contracts (Direct)
Key Figures
Option exercise price: $2.2300 per share
Underlying shares per option position: 400,000 shares
First exercise date: January 2, 2027
+4 more
7 metrics
Option exercise price
$2.2300 per share
Exercise price for CEO stock options
Underlying shares per option position
400,000 shares
Common stock underlying each option holding
First exercise date
January 2, 2027
Earliest option exercise date
Second exercise date
January 2, 2028
Second option exercise date
Third exercise date
January 2, 2029
Third option exercise date
Fourth exercise date
January 2, 2030
Fourth option exercise date
Option expiration date
January 2, 2036
Expiration for all reported options
Key Terms
Form 3, stock options, underlying security, exercise price, +1 more
5 terms
Form 3 regulatory
"OKYO Pharma Ltd filed a Form 3 showing insider holdings."
Form 3 is the initial public filing that officers, directors and large shareholders must submit to report their ownership of a company’s securities when they become insiders. It acts like an opening inventory sheet that gives investors a starting point to see who holds significant stakes and to spot later trades or potential conflicts of interest, helping assess insider confidence and transparency.
stock options financial
"The CEO holds four stock option positions over common stock."
Stock options are agreements that give a person the right to buy or sell a company's stock at a specific price within a certain time frame. They are often used as a reward or incentive, similar to a coupon that can be used later if the stock price rises, allowing the holder to make a profit.
underlying security financial
"Each option lists common stock as the underlying security."
exercise price financial
"All options share an exercise price of $2.2300 per share."
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
expiration date financial
"The options share a common expiration date in January 2036."
The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What does the OKYO Pharma (OKYO) Form 3 filing show about insider holdings?
The Form 3 shows CEO Robert John Dempsey holds four option positions, each over 400,000 OKYO Pharma common shares at an exercise price of $2.2300, with staggered future exercise dates and a common expiration in 2036.
What is the exercise price of the OKYO Pharma stock options reported on Form 3?
All four option holdings reported for OKYO Pharma’s CEO have an exercise price of $2.2300 per share. This is the price at which he can buy the underlying common stock if and when the options are exercised in future years.
When do the reported OKYO Pharma options become exercisable and when do they expire?
The options become exercisable on four different dates: January 2, 2027, January 2, 2028, January 2, 2029, and January 2, 2030. All positions are scheduled to expire on January 2, 2036, according to the filing data.
Does the OKYO Pharma Form 3 indicate recent insider buying or selling activity?
The Form 3 records existing option holdings for the CEO rather than new open-market purchases or sales. Transaction fields are classified as holdings with unknown direction, and the transaction summary shows no buy, sell, exercise, gift, or tax-withholding events.
AI-generated analysis. How Rhea-AI works. Not financial advice.
